What is the prevalence and burden of allergic conjunctivitis in adults and children in India?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Prevalence and Burden of Allergic Conjunctivitis in India Among Adults and Children

Allergic conjunctivitis affects approximately 10.1% of children and adolescents seeking eye care in India, with prevalence rates varying significantly by age group and showing the highest burden in early childhood (18.3%) and middle childhood (15.8%). 1

Prevalence by Age Groups in India

The prevalence of allergic eye disease (AED) in India shows distinct patterns across different age groups:

  • Infancy (<1 year): 0.3%
  • Toddlerhood (1-2 years): 6.6%
  • Early childhood (3-5 years): 18.3% (highest prevalence)
  • Middle childhood (6-11 years): 15.8%
  • Early adolescence (12-18 years): 8.1%
  • Late adolescence (18-21 years): 4.9% 1

This data demonstrates that allergic conjunctivitis peaks during early and middle childhood and shows a self-limiting trend by late adolescence.

Risk Factors and Demographics

Several key risk factors have been identified for allergic conjunctivitis in the Indian population:

  • Gender: Males have significantly higher risk (OR 2.05)
  • Age: Early and middle childhood carry the highest risk (OR 66.6 and 59.1 respectively)
  • Socioeconomic status: Higher socioeconomic class shows increased risk (OR 1.46)
  • Systemic allergies: History of systemic allergies substantially increases risk (OR 3.74) 1

Clinical Presentation and Burden

The burden of allergic conjunctivitis in India manifests in several ways:

Clinical Forms

  • Palpebral vernal keratoconjunctivitis: Most common form, affecting 42.8% of eyes 1
  • Seasonal allergic conjunctivitis: Most frequent form globally, though chronic forms are more commonly seen in ophthalmology referral centers 2

Complications

  • Corneal scarring: 2.4% of eyes
  • Keratoconus: 1.4% of eyes
  • Limbal stem cell deficiency: 0.4% of eyes
  • Shield ulcers: 0.3% of eyes 1

Seasonal Patterns

  • Most patients with allergic eye disease in India present during spring and summer months 1

Quality of Life Impact

Allergic conjunctivitis significantly impacts quality of life:

  • Causes substantial deterioration in quality of life for both children and adults 3
  • Can lead to irreversible visual damage in some cases 3
  • Ocular symptoms often rank as severe as nasal symptoms in patients with rhinoconjunctivitis 4
  • Reduced quality of life justifies increased attention to this condition 4

Association with Other Allergic Conditions

Allergic conjunctivitis frequently coexists with other allergic conditions:

  • Most children with allergic conjunctivitis also have allergic rhinitis 4
  • Allergic rhinitis and allergic conjunctivitis are so frequently associated that the term "allergic rhinoconjunctivitis" is often used 5
  • Ocular symptoms are present in 30-71% of patients with allergic rhinitis 2

Global Context

While the study focused on India provides specific prevalence data (10.1% among children and adolescents seeking eye care), global estimates suggest:

  • Allergic conjunctivitis affects 6-30% of the general population globally 2
  • Up to 30% of children worldwide may have allergic conjunctivitis alone or associated with allergic rhinitis 2
  • Recent studies suggest prevalence rates as high as 40% in some populations 4

Treatment Challenges

A significant challenge in managing allergic conjunctivitis is that treatment is frequently not appropriate 2. While most patients suffer from mild, intermittent episodes, approximately 30% of patients are affected by frequent episodes with intense and persistent symptoms that require more aggressive management 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.